RNA-3927 is a strong strategic fit with Recordati’s rare Metabolic portfolioCollaboration combines Moderna’s expertise in mRNA technology for ...

2026年初，生物医药行业迎来了一场期待已久的“开门红”。随着Moderna与默沙东个性化肿瘤疫苗五年随访数据的公布，mRNA技术正式宣告跨越“预防性疫苗时代”，跨入一个更为广阔、多元的治疗性产品开发的新纪元。在这场全球竞速中，中国创新力量正以差异化的技术路径，力图在肿瘤治疗与细胞基因治疗 （CGT）的交汇点，实现从并跑到领跑的跨越。

mRNA-3927 is an investigational novel mRNA-based therapeutic agent that is composed of two mRNAs encoding for normal human ...

Moderna shares surge 16% to $50 on five-year melanoma vaccine data showing 49% risk reduction. Analysts target $29.93 despite ...

Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.

CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (MRNA) today provided an update on regulatory submissions for its investigational seasonal influenza vaccine, mRNA-1010, for adults ...

If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock could revive after a 91% fall from its peak.

Moderna, Inc. vs. Novavax, Inc.: cost cuts, vaccine pipeline catalysts, and valuations. Click for this comparison of NVAX and ...

Moderna says the first doses have been administered in a trial of an HIV vaccine that uses mRNA technology, which is also used in its COVID-19 vaccine. "We believe that mRNA offers a unique ...

In a blast from the past, COVID-19 vaccine developer Moderna (NASDAQ: MRNA) just made headlines in 2026. Shares jumped up ...

In the latest trading session, Moderna (MRNA) closed at $43.00, marking a +2.8% move from the previous day. The stock's change was more than the S&P 500's daily loss of 2.06%. On the other hand, the ...